Mode
Text Size
Log in / Sign up

In STEMI patients, admission CK-MB and CPK elevation predicts adverse outcomes in a small cross-sectional studyOld Heart Tests Still Save Lives

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider CK-MB and CPK as prognostic markers in STEMI, especially where troponin access is limited.

This cross-sectional study assessed 15 patients with ST-elevation myocardial infarction (STEMI) presenting to the Punjab Institute of Cardiology in Lahore. The primary objective was to determine the prognostic significance of admission CK-MB and CPK levels in predicting adverse outcomes. No comparator group was reported, and the study design does not establish causality.

Among the 15 patients, CK-MB elevation was observed in 80% (12 of 15), and CPK elevation was also present in 80% (12 of 15). When both markers were elevated concurrently, this occurred in 73.3% (11 of 15) of the cohort. Troponin-I elevation was noted in 86.7% (13 of 15) of the patients. The study also examined associations with hematological parameters, finding that anemia affected 60% of patients, WBC elevation was present in 53.3%, and RBC reduction occurred in 40%.

A significant correlation between CK-MB and CPK levels was identified (r = 0.615, p = 0.0126). However, correlations between cardiac biomarkers and hematological parameters were weak, with p-values greater than 0.05. Electrolyte abnormalities involving sodium, potassium, or bicarbonate were not observed (0%). High-risk patients were identified in 53.3% of the cohort. The study did not report adverse events, discontinuations, or specific follow-up duration.

The authors note that CK-MB and CPK retain prognostic value in STEMI patients, particularly in resource-limited settings where troponin access may be constrained. Given the small sample size of 15 patients and the cross-sectional design, these findings should be interpreted with caution. Further research is needed to validate these observations in larger, randomized populations.

Imagine waking up with crushing chest pain. You rush to the hospital, terrified that your heart has stopped. Doctors need to know immediately if your heart muscle is dying.

For decades, the gold standard has been a test called troponin. It is very accurate. But in many parts of the world, this test is expensive or hard to get.

In these places, doctors rely on older tests. They check for enzymes called CK-MB and CPK. New research from Pakistan shows these older tests are still powerful tools.

Heart attacks kill more people than any other single cause of death globally. When a heart attack happens, heart muscle cells die. This releases chemicals into the blood.

Doctors use these chemicals to find the problem. Troponin is the best marker. It is very specific to heart muscle. However, not every hospital has the machines to run this test right away.

In low-resource settings, doctors must use what they have. They look at CK-MB and CPK. These are older markers. They can come from muscles other than the heart too. This makes them less perfect.

But they are cheap and easy to find. For a patient waiting hours for a test, an old marker is better than no marker. This study asks if these old tests can still predict who will get worse.

The surprising shift

We used to think old tests were outdated. We believed only the newest technology mattered. We thought if a test was not the latest, it was not good enough.

But here is the twist. In a group of 15 patients, the old tests worked very well. They matched the new test almost perfectly.

The study looked at patients who had a major heart attack. These are called STEMI patients. The doctors checked their blood for three things: the new troponin test, and the two old enzyme tests.

They found that 80% of patients had high levels of both old enzymes. This means their heart muscle was definitely damaged. The new test found damage in 87% of patients.

The numbers are close. The old tests did not miss the damage. They told doctors exactly what they needed to know to save lives.

Think of your heart like a factory. Inside the factory, there are tiny workers called muscle cells. When the factory gets damaged, these workers break.

When they break, they spill their contents into the bloodstream. These contents are like breadcrumbs. Doctors follow the breadcrumbs to find the broken factory.

Troponin is a special breadcrumb that only comes from the heart factory. It is very clean. But it costs money to make the test.

CK-MB and CPK are like generic breadcrumbs. They come from the heart, but also from arm muscles or leg muscles. If you tear your bicep, these breadcrumbs appear in your blood too.

In a perfect world, we only want heart breadcrumbs. But in a busy hospital with limited money, any breadcrumb helps. The study shows that even with the "generic" breadcrumbs, doctors can still see the heart attack clearly.

The researchers looked at 15 patients. They all had a confirmed heart attack. They came from a hospital in Lahore, Pakistan.

The doctors took blood from every patient on the day they arrived. They ran a full panel of tests. They checked heart enzymes, blood counts, sugar levels, and kidney function.

They used simple math to compare the results. They wanted to know if the old enzymes told the same story as the new test. They also checked if other blood numbers, like white blood cells, changed the picture.

The most important result is simple. The old enzymes worked. They showed high levels in 80% of the patients. The new test showed high levels in 87%.

This means the old tests are reliable. They do not miss the heart attack. They help doctors decide who needs urgent care.

The study also found that many patients had other issues. About 60% had anemia, which means they lacked red blood cells. Over half had high white blood cell counts, showing their bodies were fighting inflammation.

Many patients also had high sugar levels. This is common in heart attack patients. Surprisingly, their salt and potassium levels were normal. This is good news. It means their body balance was stable even during the crisis.

The researchers found that the old enzymes moved together. When one went up, the other went up. This consistency makes them trustworthy. They give a clear signal that the heart is in trouble.

But there is a catch

This doesn't mean this treatment is available yet.

The study has a big limitation. It only looked at 15 people. That is a very small group. In science, we usually need hundreds or thousands of people to be sure.

Also, all the patients came from one hospital. This means we do not know if the results work everywhere. We need to see if this holds true in other cities and countries.

The study is also very new. It was published in April 2026. Medical science moves fast, but we must wait for bigger studies to confirm these findings.

If you live in a place with limited medical resources, this news is hopeful. It means doctors can still save lives with simple, cheap tests.

You do not need to worry about the cost of the newest test if it is not available. The older tests are still valid. They can guide your doctor to the right treatment.

However, you should always talk to your doctor. They know your history and your local resources best. Do not stop taking your medicine because of what you read online.

If you have chest pain, call emergency services immediately. Do not wait to see if an old test works. Time is muscle. Every minute counts.

What happens next? Researchers need to study more patients. They will look at thousands of people to see if the pattern holds.

They will also check if these tests work in different types of heart attacks. Maybe the old tests are less useful for some specific cases.

Until then, doctors will keep using the tools they have. They will combine the old enzymes with clinical judgment. They will look at your symptoms and your history.

This research reminds us that simple tools can be powerful. We should not throw away old methods just because new ones exist. Sometimes, the basics are exactly what we need to survive.

Study Details

Study typeCohort
Sample sizen = 15
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Abstract Background: ST-elevation myocardial infarction (STEMI) is reported to be a leading cause of mortality worldwide. While cardiac troponins are the gold standard for myocardial injury detection but creatine kinase-MB (CK-MB) and total creatine phosphokinase (CPK) retain prognostic use in resource-limited settings. Objective: To evaluate the prognostic significance of admission CK-MB and CPK levels in STEMI patients and to assess their association with hematological parameters for integrated risk stratification. Methods: This cross-sectional study enrolled 15 consecutive STEMI patients from the Punjab Institute of Cardiology, Lahore, during January 2024. Comprehensive laboratory analysis including cardiac biomarkers (CK-MB, CPK, troponin-I, LDH), complete blood count, renal function, serum electrolytes, and metabolic parameters, was performed on admission. Pearson correlation and comparative statistical analyses were also conducted to assess the relationships between cardiac biomarkers and hematological indices. Results: The cohort includes 15 patients (mean age 50.1 +/- 12.2 years; 73.3% male). Cardiac biomarker elevation was prevalent: CK-MB was elevated in 12/15 (80%), CPK was elevated in 12/15 (80%), with concordant elevation in 11/15 (73.3%), which indicates extensive myocardial necrosis. Troponin-I showed the highest elevation rate at 13/15 (86.7%). Hematological abnormalities included anemia (60%), WBC elevation (53.3%), and RBC reduction (40%). Random glucose averaged 150.80 +/- 63.55 mg/dL, with 66.7% highlighted the hyperglycemia. Remarkably, electrolyte balance was preserved in all of the patients (0% sodium, potassium, and bicarbonate abnormalities), indicating maintained homeostasis. Pearson correlation analysis revealed a significant correlation between CK-MB and CPK (r = 0.615, p = 0.0126), while correlations between cardiac biomarkers and hematological parameters were weak (p > 0.05). Risk stratification identified 53.3% of patients as high-risk who required intensive management. Conclusions: CK-MB and CPK demonstrate significant concordance and retain prognostic value in STEMI patients, particularly in resource-limited settings where troponin access may be constrained. While troponin-I remains the most sensitive biomarker, combined assessment of conventional cardiac enzymes supports reliable evaluation of myocardial injury. Hematological parameters reflect systemic response but show limited correlation with cardiac biomarkers.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.